Drugs / ET-STEM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05315661 | Jul 2022 → Dec 2026 expected | frontotemporal dementia | Samsung Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ET-STEM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05315661 ↗ |
| Modality | Cell therapy | “mesenchymal stem cells preconditioned with ethionamide” NCT05315661 ↗ |
| Route | Other | “intraventricular space via an Ommaya reservoir” NCT05315661 ↗ |